日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study

免疫检查点抑制剂再次治疗复发或转移性鼻咽癌的疗效及预后模型构建：一项真实世界研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04258-y
Jiang, Yaofei; Wu, Jie; Dong, Shuhui; Zhang, Zhenyu; Bei, Weixin; Zheng, Lisheng; Xiang, Yanqun; Liu, Guoying
鼻咽癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial

卡多尼利单抗（PD-1/CTLA-4双特异性抗体）联合化疗治疗抗PD-1耐药的复发性或转移性鼻咽癌的疗效和安全性：一项单臂、开放标签的II期试验

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-03985-4
Jiang, Yaofei; Bei, Weixin; Wang, Lin; Lu, Nian; Xu, Cheng; Liang, Hu; Ke, Liangru; Ye, Yanfang; He, Shuiqing; Dong, Shuhui; Liu, Qin; Zhang, Chuanrun; Wang, Xuguang; Xia, Weixiong; Zhao, Chong; Huang, Ying; Xiang, Yanqun; Liu, Guoying
鼻咽癌
肿瘤
肿瘤免疫
PD-1
发表日期：2025
文献求助 收藏

Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy

免疫治疗时代既往接受过治疗的复发性或转移性鼻咽癌的联合治疗策略探索

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-52326-7
Jiang, Yaofei; Chen, Chun; Liu, Guoying; Fang, Ting; Lu, Nian; Bei, Weixin; Dong, Shuhui; Li, Wangzhong; Xia, Weixiong; Liang, Hu; Xiang, Yanqun
鼻咽癌
免疫/内分泌
肿瘤免疫
肿瘤
发表日期：2024
文献求助 收藏

Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors

既往接受过化疗和PD-1抑制剂治疗的转移性鼻咽癌患者二线治疗中再次使用PD-1抑制剂的疗效和安全性

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S460716
Bei, Weixin; Dong, Shuhui; Liu, Guoying; Lin, Lanfeng; Jiang, Yaofei; Lu, Nian; Li, Wangzhong; Liang, Hu; Xiang, Yanqun; Xia, Weixiong
鼻咽癌
肿瘤
肿瘤免疫
PD-1
发表日期：2024
文献求助 收藏

Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma

Epstein-Barr病毒DNA血清阳性与鼻咽癌中独特的肿瘤异质性和免疫微环境相关

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1124066
Li, Wangzhong; Lv, Shuhui; Liu, Guoying; Lu, Nian; Jiang, Yaofei; Liang, Hu; Xia, Weixiong; Xiang, Yanqun; Xie, Changqing; He, Jianxing
肿瘤
肿瘤免疫
微生物学
鼻咽癌
肿瘤异质性
免疫/内分泌
发表日期：2023
文献求助 收藏

MYO10 contributes to the malignant phenotypes of colorectal cancer via RACK1 by activating integrin/Src/FAK signaling.

MYO10 通过激活整合素/Src/FAK 信号通路，经由 RACK1 促进结直肠癌的恶性表型

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.15519
Ou Haibin, Wang Lili, Xi Ziyao, Shen Hui, Jiang Yaofei, Zhou Fuxiang, Liu Yu, Zhou Yunfeng
肿瘤
肠癌
发表日期：2022
文献求助 收藏

Long-Term Outcomes of Radical Surgery for Transverse Colon Cancer Staged from I to IIIC

I期至IIIC期横结肠癌根治性手术的长期疗效

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S244777
Jiang, Yaofei; Zou, Zhenhong; Zhang, Zulei; Zhang, Yi; Sun, Yuting; Liang, Bo
肿瘤
肠癌
肿瘤免疫
发表日期：2020
文献求助 收藏

Overexpression of lncRNA SNGH3 Predicts Unfavorable Prognosis and Clinical Outcomes in Human Cancers: Evidence from a Meta-Analysis

lncRNA SNGH3 过表达预示人类癌症预后不良和临床结局：来自荟萃分析的证据

期刊:Biomed Research International
影响因子:2.3
doi:10.1155/2020/7974034
Jiang, Yaofei; Le, Lulu
Human
肿瘤
肿瘤免疫
lncRNA
发表日期：2020
文献求助 收藏

Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma

膀胱尿路上皮癌患者免疫相关风险特征的构建

期刊:Biomed Research International
影响因子:2.3
doi:10.1155/2020/5848493
Jiang, Yaofei; Wang, Yibing; Li, Cong; Zou, Zhenhong; Liang, Bo
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2020
文献求助 收藏

Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis

CXCL1在癌症中的预后和临床病理意义：系统评价和荟萃分析

期刊:Cancer Biology & Therapy
影响因子:4.6
doi:10.1080/15384047.2019.1647056
Zhang, Zulei; Chen, Yuting; Jiang, Yaofei; Luo, Yan; Zhang, Hao; Zhan, Yakun
CXCL1
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏